Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Haydock
CEO Christophe Weber remains resolutely upbeat on the progress of Takeda's strategic transformation plan, the dividends of which he said are apparent in the leading Japanese pharma firm's fiscal year performance.
A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.
Despite a fall in overall revenue, emerging markets continued to perform strongly for AstraZeneca in the first quarter, becoming the UK group's single largest sales region globally, driven mainly by China.
The US approval of the targeted kinase inhibitor brigatinib seems to provide early validation of Takeda's recent acquisition of Ariad, but can the molecule carve its own niche amid intensifying same-class competition?
Novartis's South Korean subsidiary has been hit with a new fine of around $49m and reimbursement suspensions for a number of its drugs under a new ministerial action related to illegal "rebate" payments made to prescribers.
Amid recent progress for its lead molecule, ASLAN has firmed up plans for the timing of its initial public offering, which is now expected to take place in Taiwan mid May with the newly listed shares set to begin trading in early June.